What is Niki BioSolutions, Inc.?
, through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 5.15M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.